In Formycon’s earnings report, the German company revealed that its acquisition of 2 biosi...

Formycon: Biosimilar Acquisitions, Developments Signal Hope Despite Losses – The Center for Biosimilars

In Formycon’s earnings report, the German company revealed that its acquisition of 2 biosimilar candidates, FYB201 and FYB202, has been completed and development of biosimilars FYB208 and FYB209 has commenced.In April 2022, Formycon announced the…

 

Read the full article here


-- END RSP MOD -->